Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Young TILs and Aldesleukin in Advanced NSCLC
NCT02133196Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2014
- Primary completion
- Oct 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of young tumor-infiltrating lymphocytes in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Oct 2014; status: recruiting.
02
Drugs
young tumor-infiltrating lymphocytes
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02133196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133196.